Cancer Research Technology
Log in Register
Menu

Info

Catalogue Number 152839
Parental Line SJSA-1
Host Human
Tissue Bone
Disease Keywords Osteosarcoma; Multipotential sarcoma
Model Cancer Model
Relevance To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, MI-63, and a clonal resistant cell line was generated. The p53 mediated responses of the parental and resistant cell line were compared. In contrast to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was not observed in the SJSA-1 derived cell line, S-M6R1.
Production Details Resistant cell lines were established by exposing SJSA-1 cells to MI-63. Single cell derived colonies were isolated with cloning cylinders and the clonal population expanded in culture medium containing the MDM2/p53 antagonist refreshed weekly for 60 days. Stage 1 resistant clones were then further exposed to increased concentrations of MI-63 for 30 days to generate stage 2 resistant clones.
Conditional No
Research Area Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, Drug Discovery & Development, Epigenetics & Nuclear Signalling
Cellosaurus ID CVCL_HG09

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.

Europe PMC ID: 27323823

Drummond et al. 2016. Oncotarget. :. PMID: 27323823.


Add a reference

References: 2 entries

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.

Drummond et al. 2016. Oncotarget. :. PMID: 27323823.


Add a reference